Skip to main content
Clinical Trials/NCT03809078
NCT03809078
Completed
Phase 2

A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Andrei Iagaru1 site in 1 country14 target enrollmentJanuary 14, 2019

Overview

Phase
Phase 2
Intervention
68Ga-PSMA-11
Conditions
Prostate Cancer
Sponsor
Andrei Iagaru
Enrollment
14
Locations
1
Primary Endpoint
Number of Participants With Biopsy Results Correlated With PET Based Imaging Findings
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.

Detailed Description

Primary Objective: To evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer. Exploratory Objective: * Correlation of 68Ga PSMA 11 uptake and Gleason score at biopsy * Correlation of 68Ga RM2 and Gleason score at biopsy

Registry
clinicaltrials.gov
Start Date
January 14, 2019
End Date
March 8, 2022
Last Updated
2 years ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Andrei Iagaru

Professor of Radiology (Nuclear Medicine)

Stanford University

Eligibility Criteria

Inclusion Criteria

  • Suspected prostate cancer
  • Planned prostate biopsy
  • Able to provide written consent
  • Karnofsky performance status of 50 (or ECOG/WHO equivalent)

Exclusion Criteria

  • Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam
  • Metallic implants (contraindicated for MRI)

Arms & Interventions

68Ga PSMA11 first followed by 68Ga RM2

Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2

Intervention: 68Ga-PSMA-11

68Ga RM2 first followed by 68Ga PSMA11

Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11

Intervention: 68Ga RM2

68Ga RM2 first followed by 68Ga PSMA11

Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11

Intervention: 68Ga-PSMA-11

68Ga RM2 first followed by 68Ga PSMA11

Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11

Intervention: Investigational PET scanner coils and software

68Ga PSMA11 first followed by 68Ga RM2

Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2

Intervention: 68Ga RM2

68Ga PSMA11 first followed by 68Ga RM2

Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2

Intervention: Investigational PET scanner coils and software

Outcomes

Primary Outcomes

Number of Participants With Biopsy Results Correlated With PET Based Imaging Findings

Time Frame: Up to approximately 2 hours to complete each scan

Measure of PET based Biopsy Guidance (ie, prostate uptake on 68Ga PSMA 11 and 68Ga RM2 scans).

Study Sites (1)

Loading locations...

Similar Trials